Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0LJ9D
|
||||
Former ID |
DNC011110
|
||||
Drug Name |
4-(4-(thiophen-2-yl)benzyl)pyridine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [531085] | ||
Structure |
Download2D MOL |
||||
Formula |
C16H13NS
|
||||
Canonical SMILES |
C1=CSC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
|
||||
InChI |
1S/C16H13NS/c1-2-16(18-11-1)15-5-3-13(4-6-15)12-14-7-9-17-10-8-14/h1-11H,12H2
|
||||
InChIKey |
ORQOALYZYXEWJV-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [531085] | |
17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [531085] | ||
PathWhiz Pathway | SteroidogenesisPW000045:Androgen and Estrogen Metabolism | ||||
Steroidogenesis | |||||
WikiPathways | Metapathway biotransformation | ||||
Oxidation by Cytochrome P450 | |||||
Metabolism of steroid hormones and vitamin D | |||||
Corticotropin-releasing hormoneWP702:Metapathway biotransformation | |||||
Steroid Biosynthesis | |||||
Glucocorticoid & Mineralcorticoid Metabolism | |||||
Prostate Cancer | |||||
Phase 1 - Functionalization of compounds | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.